Novartis AG (LON:0K9E)

London flag London · Delayed Price · Currency is GBP · Price in USD
163.38
+0.05 (0.03%)
At close: Feb 20, 2026
Market Cap230.69B +38.1%
Revenue (ttm)42.11B +9.6%
Net Income10.39B +17.1%
EPS5.31 +21.8%
Shares Outn/a
PE Ratio22.20
Forward PE18.34
Dividend2.61 (1.60%)
Ex-Dividend DateMar 12, 2025
Volume695
Average Volume76,167
Open163.60
Previous Close163.33
Day's Range162.00 - 163.60
52-Week Range97.51 - 167.85
Beta0.45
RSI72.41
Earnings DateFeb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]

Industry Pharmaceutical Preparations
Founded 1996
Employees 75,267
Stock Exchange London Stock Exchange
Ticker Symbol 0K9E
Full Company Profile

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Financial numbers in USD Financial Statements